Ascidian Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2020-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.ascidian-tx.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
Phase 1
Recruiting
- Conditions
- Stargardt DiseaseCone Rod DystrophyJuvenile Macular DegenerationStargardt Disease 1
- Interventions
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Ascidian Therapeutics, Inc
- Target Recruit Count
- 13
- Registration Number
- NCT06467344
- Locations
- 🇺🇸
University of San Francisco, San Francisco, California, United States
🇺🇸Vitreo Retinal Associates, Gainesville, Florida, United States
🇺🇸Bascom Palmer Eye Institute, Miami, Florida, United States
Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials
Recruiting
- Conditions
- Cone Rod DystrophyJuvenile Macular DegenerationStargardt DiseaseStargardt Disease 1
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Ascidian Therapeutics, Inc
- Target Recruit Count
- 50
- Registration Number
- NCT06445322
- Locations
- 🇺🇸
University of San Francisco, San Francisco, California, United States
🇺🇸Vitreo Retinal Associates, Gainesville, Florida, United States
🇺🇸Wilmer Eye Institute at John Hopkins, Baltimore, Maryland, United States
News
No news found